Spots Global Cancer Trial Database for avastin
Every month we try and update this database with for avastin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER) | NCT00473590 | Multiple Myelom... | Bevacizumab Bortezomib placebo | 18 Years - | Genentech, Inc. | |
| A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma | NCT00434252 | Melanoma | bevacizumab carboplatin paclitaxel placebo | 18 Years - | Genentech, Inc. | |
| LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | NCT00859222 | Malignant Gliom... | LBH589 bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma | NCT00782275 | Renal Cell Carc... Kidney Cancer | bevacizumab temsirolimus | 18 Years - | Dana-Farber Cancer Institute | |
| Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma | NCT00081861 | Lymphoma | Avastin Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Molecular Triaging of Newly Diagnosed Breast Cancer | NCT01159236 | Breast Cancer | Paclitaxel Fluorouracil Doxorubicin Epirubicin Cyclophosphamid... Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer | NCT00130728 | Non-Small Cell ... | bevacizumab erlotinib HCl placebo | 18 Years - | Genentech, Inc. | |
| Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer | NCT03272217 | Urothelial Carc... | Atezolizumab Bevacizumab | 18 Years - | Hoosier Cancer Research Network | |
| High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors | NCT00936936 | Testicular Canc... | Gemcitabine Docetaxel Melphalan Carboplatin Mesna Ifosfamide Etoposide Stem Cell Trans... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g) | NCT00851136 | Metastatic Colo... | bevacizumab FOLFOX PRO95780 | 18 Years - | Genentech, Inc. | |
| LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | NCT00859222 | Malignant Gliom... | LBH589 bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies | NCT00856180 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... | Bevacizumab Cyclophosphamid... | 18 Years - | Dana-Farber Cancer Institute | |
| A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS) | NCT00257608 | Non-Small Cell ... | bevacizumab placebo erlotinib HCl | 18 Years - | Genentech, Inc. | |
| A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B) | NCT00434356 | Metastatic Brea... | bevacizumab sunitinib paclitaxel | 18 Years - | Genentech, Inc. | |
| A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer | NCT00114946 | Colorectal Canc... | Avastin | 18 Years - | Genentech, Inc. | |
| Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas | NCT05745857 | Barrett's Esoph... Barrett Oesopha... Esophageal Aden... | Avastin Erbitux Fluorescence en... | 18 Years - | University Medical Center Groningen | |
| Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer | NCT00503906 | Breast Cancer | Avastin Gemcitabine Abraxane | 18 Years - 120 Years | University of Miami | |
| Doxil, Bevacizumab and Temsirolimus Trial | NCT00761644 | Advanced Cancer | Doxil Bevacizumab Temsirolimus | 12 Years - | M.D. Anderson Cancer Center | |
| Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma | NCT01582152 | Brain Neoplasms Central Nervous... | TPI287 Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases | NCT01972490 | Colorectal Neop... | avastin mFOLFOX6 | 18 Years - 75 Years | Fudan University | |
| Doxil, Bevacizumab and Temsirolimus Trial | NCT00761644 | Advanced Cancer | Doxil Bevacizumab Temsirolimus | 12 Years - | M.D. Anderson Cancer Center | |
| A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) | NCT00735436 | Malignant Gliom... Glioblastoma Mu... Gliosarcoma | Gliadel/Avastin... | 18 Years - | Duke University | |
| Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients | NCT00952003 | Gastric Cancer Unresectable | Oxaliplatin, Ir... | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| AMG 102 and Avastin for Recurrent Malignant Glioma | NCT01113398 | Glioblastoma Mu... Gliosarcoma | AMG 102 Avastin | 18 Years - | Duke University | |
| Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) | NCT05446870 | High-grade Sero... Ovarian Carcino... | Pembrolizumab Paclitaxel Carboplatin Avastin MK-4830 Docetaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Bevacizumab for Recurrent Malignant Glioma | NCT00271609 | Recurrent High-... Malignant Gliom... | Bevacizumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma | NCT00501891 | Glioblastoma Mu... | Bevacizumab Metronomic Temo... | 18 Years - | Duke University | |
| Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas | NCT00612339 | Glioblastoma Gliosarcoma | Avastin and Tem... | 18 Years - | Duke University | |
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | NCT04430842 | Astrocytoma Brain Cancer Brain Metastase... Bladder Cancer Breast Cancer Cervical Cancer Cholangiocarcin... Colorectal Canc... Esophagus Cance... Gastric Cancer Head and Neck C... Kidney Cancer Liver Cancer Lung Cancer Melanoma Ovarian Cancer Pancreatic Canc... Pleural Mesothe... Prostate Cancer Sarcoma Tongue Cancer Thymic Carcinom... Urinary Tract C... | QBS10072S | 18 Years - | Quadriga Biosciences, Inc. | |
| Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma | NCT00142467 | Hepatocellular ... | Gemcitabine Oxaliplatin Bevacizumab | 18 Years - | Massachusetts General Hospital | |
| A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g) | NCT00851136 | Metastatic Colo... | bevacizumab FOLFOX PRO95780 | 18 Years - | Genentech, Inc. | |
| Ph II Bevacizumab + Etoposide for Pts w Recurrent MG | NCT00612430 | Glioblastoma Gliosarcoma | Bevacizumab and... | 18 Years - | Duke University | |
| An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO) | NCT00726661 | Breast Cancer | - | Genentech, Inc. | ||
| Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers | NCT01121939 | Neuroendocrine ... | Bevacizumab Pertuzumab Sandostatin LAR... | 18 Years - | SCRI Development Innovations, LLC | |
| A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT) | NCT00312728 | Non-Small Cell ... Brain Neoplasms | bevacizumab First-Line Chem... Second-Line Che... | 18 Years - | Genentech, Inc. | |
| Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma | NCT00137826 | Mesothelioma | Erlotinib Bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) | NCT02664961 | Gestational Tro... Choriocarcinoma Placental Site ... Epithelioid Tro... | TRC105 Bevacizumab | 16 Years - 99 Years | Tracon Pharmaceuticals Inc. | |
| Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab | NCT02330562 | Malignant Gliom... Glioblastoma | MRZ BEV | 18 Years - | Celgene | |
| BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer | NCT01263782 | Lung Cancer | Carboplatin Pemetrexed Bevacizumab Cixutumumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES) | NCT00388206 | Colorectal Canc... Non-Small Cell ... | - | Genentech, Inc. | ||
| Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer | NCT02272413 | Carcinoma, Non-... | BI 695502 Avastin | 18 Years - | Boehringer Ingelheim | |
| Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme | NCT00883298 | Recurrent Gliob... Recurrent Glios... | temozolomide an... | 18 Years - 83 Years | Center for Neurosciences, Tucson | |
| Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma | NCT00883688 | Brain Cancer Pediatric Cance... | Bevacizumab Lapatinib | - 21 Years | M.D. Anderson Cancer Center | |
| Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF) | NCT00095706 | Breast Cancer | Bevacizumab (dr... | 18 Years - 75 Years | Translational Oncology Research International | |
| To Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer | NCT03676192 | Adenocarcinoma ... | CT-16 Avastin | 18 Years - | Celltrion | |
| A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) | NCT00491738 | Renal Cell Carc... | bevacizumab sunitinib placebo | 18 Years - | Genentech, Inc. | |
| Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies | NCT00856180 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... | Bevacizumab Cyclophosphamid... | 18 Years - | Dana-Farber Cancer Institute | |
| Bevacizumab in Metastatic Renal Cancer | NCT02627144 | Renal Cell Canc... | Bevacizumab Interferon alph... | 18 Years - | Hoffmann-La Roche | |
| Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC | NCT00960297 | Non-Small Cell ... | Carboplatin Paclitaxel Bevacizumab | 18 Years - | SCRI Development Innovations, LLC | |
| Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery | NCT00242502 | Hepatocellular ... Liver Cancer | Bevacizumab (Av... Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence | NCT01526837 | Glioblastoma Mu... | Avastin | 18 Years - | Brain & Spine Surgeons of New York | |
| Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma | NCT00782275 | Renal Cell Carc... Kidney Cancer | bevacizumab temsirolimus | 18 Years - | Dana-Farber Cancer Institute | |
| A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2) | NCT00281697 | Metastatic Brea... | Bevacizumab Placebo Standard chemot... | 18 Years - | Genentech, Inc. | |
| Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients | NCT00354978 | Colorectal Canc... | 5-Fluorouracil Bevacizumab Leucovorin Irinotecan | 18 Years - | M.D. Anderson Cancer Center | |
| Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated | NCT01332721 | Adult Solid Tum... | TRC105 and Beva... | 18 Years - | Tracon Pharmaceuticals Inc. | |
| Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers | NCT01121939 | Neuroendocrine ... | Bevacizumab Pertuzumab Sandostatin LAR... | 18 Years - | SCRI Development Innovations, LLC | |
| Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma | NCT00113217 | Renal Cell Carc... Kidney Cancer | Bevacizumab | - | M.D. Anderson Cancer Center | |
| Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | NCT00613028 | Glioblastoma Gliosarcoma | Temo + Avastin VP-16 + Avastin | 18 Years - | Duke University | |
| Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | NCT01183663 | Advanced Cancer... | Lenalidomide Bevacizumab Sorafenib Temsirolimus Lenalidomide Oxaliplatin Leucovorin 5-fluorouracil | 18 Years - | M.D. Anderson Cancer Center | |
| Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer | NCT00361231 | Biliary Tract C... Gallbladder Ade... | Bevacizumab Gemcitabine Oxaliplatin | 18 Years - | Massachusetts General Hospital | |
| Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery | NCT02884648 | Malignant Neopl... Ovarian Cancer Fallopian Tube ... Primary Periton... | Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | NCT00613028 | Glioblastoma Gliosarcoma | Temo + Avastin VP-16 + Avastin | 18 Years - | Duke University | |
| A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer | NCT00114946 | Colorectal Canc... | Avastin | 18 Years - | Genentech, Inc. | |
| XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib | NCT00920868 | Solid Tumor Metastatic Colo... | dasatinib bevacizumab Oxaliplatin Capecitabine | 18 Years - | Duke University | |
| Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer | NCT01187199 | Advanced Cancer | Temsirolimus Bevacizumab Paclitaxel Sorafenib Carboplatin | - | M.D. Anderson Cancer Center | |
| Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated | NCT01332721 | Adult Solid Tum... | TRC105 and Beva... | 18 Years - | Tracon Pharmaceuticals Inc. | |
| Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | NCT00511992 | Advanced Ovaria... Primary Periton... Ovarian Carcino... | Avastin Paclitaxel Cisplatin | 18 Years - | University of Oklahoma | |
| Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure | NCT01954030 | Malignant Gliom... | CTO and Bevaciz... CTO alone | 18 Years - | Duke University | |
| Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer | NCT00866723 | Ovarian Cancer Primary Periton... Fallopian Tube ... | bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver | NCT00980239 | Liver Cancer Advanced Cancer | Irinotecan Bevacizumab Oxaliplatin Cetuximab | - | M.D. Anderson Cancer Center | |
| To Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer | NCT03676192 | Adenocarcinoma ... | CT-16 Avastin | 18 Years - | Celltrion | |
| XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib | NCT00920868 | Solid Tumor Metastatic Colo... | dasatinib bevacizumab Oxaliplatin Capecitabine | 18 Years - | Duke University | |
| Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer | NCT00846612 | Ovarian Cancer | Doxil Bevacizumab (Av... | 18 Years - | NYU Langone Health | |
| Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin | NCT00507585 | Liver Cancer Advanced Solid ... | Fluorouracil Avastin Leucovorin Oxaliplatin | - | M.D. Anderson Cancer Center | |
| A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer | NCT00483834 | Colorectal Canc... | Bevacizumab Irinotecan Capecitabine | 18 Years - | University Health Network, Toronto | |
| Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer | NCT00642759 | Non-small Cell ... | carboplatin Nab-paclitaxel Bevacizumab | 18 Years - | Massachusetts General Hospital | |
| Bevacizumab in Metastatic Renal Cancer | NCT02627144 | Renal Cell Canc... | Bevacizumab Interferon alph... | 18 Years - | Hoffmann-La Roche | |
| Bevacizumab and Bortezomib in Patients With Advanced Malignancy | NCT00428545 | Advanced Malign... Lymphoma Myeloma Solid Tumors | Bevacizumab Bortezomib | - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
